Thomas Jefferson University

Rita Axelrod

TitleProfessor
InstitutionThomas Jefferson University
DepartmentMedical Oncology
Address1025 Walnut St.
Philadelphia PA 19107
Phone215-955-8874
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Johnson JM, Vathiotis IA, Harshyne LA, Ali A, Bar Ad V, Axelrod R, Lorber E, Curry J, Cognetti DM, Luginbuhl AJ, Tuluc M, Keith S, Mahoney MG, Argiris A. Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck. J Immunother Cancer. 2023 08; 11(8). PMID: 37536941.
      Citations:    
    2. Reck M, Ciuleanu TE, Lee JS, Schenker M, Zurawski B, Kim SW, Mahave M, Alexandru A, Peters S, Pluzanski A, Caro RB, Linardou H, Burgers JA, Nishio M, Martinez-Marti A, Azuma K, Axelrod R, Paz-Ares LG, Ramalingam SS, Borghaei H, O'Byrne KJ, Li L, Bushong J, Gupta RG, Grootendorst DJ, Eccles LJ, Brahmer JR. Systemic and intracranial outcomes with first-line nivolumab plus ipilimumab in patients with metastatic non-small cell lung cancer and baseline brain metastases from CheckMate 227 Part 1. J Thorac Oncol. 2023 May 03. PMID: 37146754.
      Citations:    
    3. Ali AS, Msanukian G, Johnson JM, Vathiotis I, Axelrod R, Keith SW, Md JC, Md DC, Md AL, Argiris A, Bar-Ad V. In-field toxicity analysis of a phase I clinical trial of nivolumab and ipilimumab with definitive radiation therapy in locally advanced squamous cell carcinoma of the head and neck: In-Field toxicity of immune-RT in LA-SCCHN. Int J Radiat Oncol Biol Phys. 2023 Apr 03. PMID: 37019367.
      Citations:    
    4. Caudell JJ, Torres-Saavedra PA, Rosenthal DI, Axelrod RS, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, El-Naggar AK, Konski AA, Echevarria MI, Dunlap NE, Shenouda G, Singh AK, Beitler JJ, Garsa A, Bonner JA, Garden AS, Algan O, Harris J, Le QT. Long-term update of NRG/RTOG 0522: a randomized phase III trial of concurrent radiation and cisplatin with or without cetuximab in locoregionally advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2022 Dec 19. PMID: 36549347.
      Citations:    
    5. Luginbuhl AJ, Johnson JM, Harshyne LA, Linnenbach AJ, Shukla SK, Alnemri A, Kumar G, Cognetti DM, Curry JM, Kotlov N, Antysheva Z, Degryse S, Mannion K, Gibson MK, Netterville J, Brown B, Axelrod R, Zinner R, Tuluc M, Gargano S, Leiby BE, Shimada A, Mahoney MG, Martinez-Outschoorn U, Rodeck U, Kim YJ, South AP, Argiris A. Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2022 Mar 01; 28(5):915-927. PMID: 34911681.
      Citations:    
    6. Merlino DJ, Johnson JM, Tuluc M, Gargano S, Stapp R, Harshyne L, Leiby BE, Flanders A, Zinner R, Axelrod R, Curry J, Cognetti DM, Mannion K, Kim YJ, Rodeck U, Argiris A, Luginbuhl AJ. Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect. Front Oncol. 2020; 10:566315. PMID: 33344227.
      Citations:    
    7. Man LC, Axelrod R. Not All Head and Neck Squamous Cell Carcinomas Are Created Equal: Some Are More Aggressive. Int J Radiat Oncol Biol Phys. 2017 Dec 01; 99(5):1063. PMID: 29165276.
      Citations:    
    8. Weidhaas JB, Harris J, Schaue D, Chen AM, Chin R, Axelrod R, El-Naggar AK, Singh AK, Galloway TJ, Raben D, Wang D, Matthiesen C, Avizonis VN, Manon RR, Yumen O, Nguyen-Tan PF, Trotti A, Skinner H, Zhang Q, Ferris RL, Sidransky D, Chung CH. The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2017 Apr 01; 3(4):483-491. PMID: 28006059.
      Citations:    
    9. Wirth LJ, Dakhil S, Kornek G, Axelrod R, Adkins D, Pant S, O'Brien P, Debruyne PR, Oliner KS, Dong J, Murugappan S. PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2016 Oct; 61:31-40. PMID: 27688102.
      Citations:    
    10. Truong MT, Zhang Q, Rosenthal DI, List M, Axelrod R, Sherman E, Weber R, Nguyen-Tân PF, El-Naggar A, Konski A, Galvin J, Schwartz D, Trotti A, Silverman C, Singh A, Godette K, Bonner JA, Jones CU, Garden AS, Shenouda G, Matthiesen C, Le QT, Bruner D. Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522. Int J Radiat Oncol Biol Phys. 2016 Aug 12. PMID: 27727066.
      Citations:    
    11. Ahn PH, Machtay M, Anne PR, Cognetti D, Keane WM, Wuthrick E, Dicker AP, Axelrod RS. Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck Cancer. Am J Clin Oncol. 2016 Jul 07. PMID: 27391356.
      Citations:    
    12. Bar-Ad V, Zhang QE, Harari PM, Axelrod R, Rosenthal DI, Trotti A, Jones CU, Garden AS, Song G, Foote RL, Raben D, Shenouda G, Spencer SA, Harris J, Le QT. Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience. Int J Radiat Oncol Biol Phys. 2016 Aug 1; 95(5):1346-54. PMID: 27212198.
      Citations:    
    13. Axelrod RS, Sherman E, Garden A, Nguyen-Tan PF, Trotti A, Yom SS, Zhang Q. Reply to d. Adkins et Al. J Clin Oncol. 2015 Apr 1; 33(10):1224-5. PMID: 25713438.
      Citations:    
    14. Ramalingam SS, Shtivelband M, Soo RA, Barrios CH, Makhson A, Segalla JG, Pittman KB, Kolman P, Pereira JR, Srkalovic G, Belani CP, Axelrod R, Owonikoko TK, Qin Q, Qian J, McKeegan EM, Devanarayan V, McKee MD, Ricker JL, Carlson DM, Gorbunova VA. Randomized Phase II Study of Carboplatin and Paclitaxel With Either Linifanib or Placebo for Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2015 Feb 10; 33(5):433-41. PMID: 25559798.
      Citations:    
    15. Bar-Ad V, Palmer J, Yang H, Cognetti D, Curry J, Luginbuhl A, Tuluc M, Campling B, Axelrod R. Current management of locally advanced head and neck cancer: the combination of chemotherapy with locoregional treatments. Semin Oncol. 2014 Dec; 41(6):798-806. PMID: 25499638.
      Citations:    
    16. Bar-Ad V, Leiby B, Witek M, Xiao Y, Cui Y, Dai Y, Cao J, Axelrod R, Campling B, Both S, Werner-Wasik M. Treatment-related Acute Esophagitis For Patients With Locoregionally Advanced Non-Small Cell Lung Cancer Treated With Involved-field Radiotherapy and Concurrent Chemotherapy. Am J Clin Oncol. 2014 Oct; 37(5):433-7. PMID: 23388558.
      Citations:    
    17. Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar AK, Gillison ML, Jordan RC, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014 Sep 20; 32(27):2940-50. PMID: 25154822.
      Citations:    
    18. Wuthrick EJ, Curran WJ, Camphausen K, Lin A, Glass J, Evans J, Andrews DW, Axelrod R, Shi W, Werner-Wasik M, Haacke EM, Hillman GG, Dicker AP. A pilot study of hypofractionated stereotactic radiation therapy and sunitinib in previously irradiated patients with recurrent high-grade glioma. Int J Radiat Oncol Biol Phys. 2014 Oct 1; 90(2):369-75. PMID: 25104067.
      Citations:    
    19. Zhang K, Lai Y, Axelrod R, Campling B, Hyslop T, Civan J, Solomides C, Myers RE, Lu B, Bar Ad V, Li B, Ye Z, Yang H. Modeling the overall survival of patients with advanced-stage non-small cell lung cancer using data of routine laboratory tests. Int J Cancer. 2015 Jan 15; 136(2):382-91. PMID: 24866905.
      Citations:    
    20. Owonikoko TK, Aisner J, Wang XV, Dahlberg SE, Rubin EH, Ramalingam SS, Gounder M, Rausch PG, Axelrod RS, Schiller JH. E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer. Cancer Chemother Pharmacol. 2014 Jan; 73(1):171-80. PMID: 24288121.
      Citations:    
    21. Arana Yi C, McCue P, Rosen M, Machtay M, Axelrod R, Morris GJ. Sarcoidosis mimicking metastatic bone disease in head and neck cancer. Semin Oncol. 2013 Oct; 40(5):529-34. PMID: 24135396.
      Citations:    
    22. Zaorsky NG, Sun Y, Wang Z, Palmer J, Fortina PM, Solomides C, Werner-Wasik M, Dicker AP, Axelrod R, Campling B, Evans N, Cowan S, Lu B. Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab. Cancer Biol Ther. 2013 Oct 1; 14(10):883-7. PMID: 23917487.
      Citations:    
    23. Lawrence YR, Paulus R, Langer C, Werner-Wasik M, Buyyounouski MK, Komaki R, Machtay M, Smith C, Axelrod RS, Wasserman T, Bradley JD, Movsas B. The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: Long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801. Lung Cancer. 2013 Jun; 80(3):298-305. PMID: 23477890.
      Citations:    
    24. Lieberthal RD, Dudash K, Axelrod R, Goldfarb NI. An economic model to value companion diagnostics in non-small-cell lung cancer. Per Med. 2013 Mar; 10(2):139-147. PMID: 29758848.
      Citations:    
    25. Fogh SE, Kubicek GJ, Champ C, Intenzo C, Axelrod R, Keane WM, Machtay MM. Value of fluoro-2-deoxy-D-glucose-positron emission tomography for detecting metastatic lesions in head and neck cancer. Am J Clin Oncol. 2012 Aug; 35(4):311-5. PMID: 22772424.
      Citations:    
    26. Kubicek GJ, Axelrod RS, Machtay M, Ahn PH, Anne PR, Fogh S, Cognetti D, Myers TJ, Curran WJ, Dicker AP. Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 2012 Jul 15; 83(4):1192-7. PMID: 22245208.
      Citations:    
    27. Zussman B, Gonzalez LF, Dumont A, Tjoumakaris S, Rosenwasser R, Hasan D, Cognetti D, Axelrod R, Jabbour P. Endovascular management of carotid blowout. World Neurosurg. 2012 Jul; 78(1-2):109-14. PMID: 22120297.
      Citations:    
    28. Wuthrick EJ, Kamrava M, Curran WJ, Werner-Wasik M, Camphausen KA, Hyslop T, Axelrod R, Andrews DW, Glass J, Machtay M, Dicker AP. A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies. Cancer. 2011 Dec 15; 117(24):5548-59. PMID: 21647871.
      Citations:    
    29. Shen X, Denittis A, Werner-Wasik M, Axelrod R, Gilman P, Meyer T, Treat J, Curran WJ, Machtay M. Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma. Radiat Oncol. 2011; 6:17. PMID: 21324160.
      Citations:    
    30. Argiris A, Ghebremichael M, Burtness B, Axelrod RS, Deconti RC, Forastiere AA. A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303). Cancer. 2011 Aug 1; 117(15):3374-82. PMID: 21246525.
      Citations:    
    31. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010 Jul 1; 363(1):24-35. PMID: 20530316.
      Citations:    
    32. Axelrod RS. Introduction: women and lung cancer. Semin Oncol. 2009 Dec; 36(6):504-5. PMID: 19995641.
      Citations:    
    33. Fogh S, Machtay M, Werner-Wasik M, Curran WJ, Bonanni R, Axelrod R, Andrews D, Dicker AP. Phase I trial using patupilone (epothilone B) and concurrent radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys. 2010 Jul 15; 77(4):1009-16. PMID: 19879067.
      Citations:    
    34. Argiris A, Buchanan A, Brockstein B, Kolesar J, Ghebremichael M, Pins M, Hahn K, Axelrod R, Forastiere A. Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group. Cancer. 2009 Oct 1; 115(19):4504-13. PMID: 19634157.
      Citations:    
    35. Lilenbaum R, Axelrod R, Thomas S, Dowlati A, Seigel L, Albert D, Witt K, Botkin D. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol. 2008 Feb 20; 26(6):863-9. PMID: 18281658.
      Citations:    
    36. Cupino A, Axelrod R, Anne PR, Sidhu K, Lavarino J, Kung B, Rosen M, Keane W, Machtay M. Neck dissection followed by chemoradiotherapy for stage IV (N+) oropharynx cancer. Otolaryngol Head Neck Surg. 2007 Sep; 137(3):416-21. PMID: 17765768.
      Citations:    
    37. Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, Akerley W, Kelly K, Limentani SA, Crawford J, Reimers HJ, Axelrod R, Kashala O, Sheng S, Schiller JH. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2006 Nov 1; 24(31):5025-33. PMID: 17075122.
      Citations:    
    38. Movsas B, Scott C, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Smith C, Axelrod R, Sarna L, Wasserman T, Byhardt R. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol. 2005 Apr 1; 23(10):2145-54. PMID: 15800308.
      Citations:    
    39. Werner-Wasik M, Axelrod RS, Friedland DP, Hauck W, Rose LJ, Chapman AE, Grubbs S, Deshields M, Curran WJ. Phase II: trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemoradiotherapy. Semin Radiat Oncol. 2002 Jan; 12(1 Suppl 1):34-9. PMID: 11917282.
      Citations:    
    Axelrod's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (107)
    Explore
    _
    Co-Authors (46)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _